CSF3 and anemia: The most frequent significant AEs were related to hematological toxicity, with grade 3–4 anemia in 26 patients (37.7%), grade 3–4 neutropenia in 17 patients (24.6%) (including 6 patients (8.7%) presenting febrile neutropenia (4 of whom were patients who did not undergo any G-CSF prophylaxis)), and grade 3–4 thrombopenia in 9 patients (13%).